Key result
Platelet factor 4 carboxy-terminal peptides inhibit murine megakaryocytopoiesis, an effect neutralized by heparin.
Why the study?
The inhibitory effect of platelet factor 4 and its carboxy-terminal peptides on murine megakaryocytopoiesis and the role of heparin in neutralizing this activity were not fully characterized.
Population
Murine models and human megakaryoblastic cell lines (HEL, Meg-01, Dami)
Comparison
Carboxy-terminal peptides of PF4 (C1-24, C13-24, C1-13) with or without heparin
Design
Preclinical in vivo and in vitro study
Authors
Loading...
May modulate megakaryocytopoiesis via heparin-binding domains in murine models; leaves open human translation and clinical relevance.
The inhibitory activity of PF4 on megakaryocytopoiesis is localized to a short carboxy-terminal region (13-24) that likely includes its heparin-binding domain.
Lebeurier et al. (1996) studied Murine megakaryocytopoiesis. Carboxy-terminal peptides (C1-24 and C13-24) of platelet factor 4 vs. C1-13 peptide was evaluated on Inhibition of murine megakaryocytopoiesis. Carboxy-terminal peptides (C1-24 and C13-24) of platelet factor 4 inhibit murine megakaryocytopoiesis in vivo and in vitro, an effect that is neutralized by heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: